Amicus Therapeutics (FOLD) Reports Positive Phase 3 Data From Fabry Monotherapy Study 012
Tweet Send to a Friend
Amicus Therapeutics (Nasdaq: FOLD) announced additional positive data on important secondary endpoints from its second Phase 3 study (Study 012) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
